logo image
search icon
Neostigmine Methylsulfate Injection Market

Neostigmine Methylsulfate Injection Market Size, Share & Trends Analysis Report By Application (Myasthenia Gravis, Reversal Of Neuromuscular Blockade), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By End User, By Region, And by Segment Forecasts, 2023-2031

Report ID : 2046 | Published : 2024-10-28 | Pages: 175 | Format: PDF/EXCEL

The Neostigmine Methylsulfate Injection Market Size is valued at USD 156.54 Mn in 2022 and is predicted to reach USD 228.43 Mn by the year 2031 at a 4.4% CAGR during the forecast period for 2023-2031.

Neostigmine Methylsulfate Injection Market

Neostigmine methylsulfate is a reversible cholinesterase inhibitor. Cholinesterases are enzymes responsible for breaking down the neurotransmitter acetylcholine at the neuromuscular junction. By inhibiting these enzymes, neostigmine allows acetylcholine to accumulate, leading to increased stimulation of skeletal muscle. A unique stability-indicating reverse phase HPLC method was created and validated for the quantitative determination of associated impurities and degradation impurities in neostigmine methylsulfate API and injectable formulation. 

A popular quaternary ammonium chemical called methyl sulphate is utilized as a competitive cholinesterase inhibitor. It raises the levels of acetylcholine by reducing its breakdown in the synaptic cleft. As a non-depolarizing neuromuscular blocking drug, this acetylcholine competes for the binding sites and breaks the neuromuscular blockade. The nicotinic and muscarinic actions are amplified as a result. It makes the skeletal muscles active. 

Since neostigmine methylsulfate cannot easily cross the blood-brain barrier, the central nervous system is unaffected. Neostigmine methylsulfate does not absorb well into the digestive system because of its ionic composition. As a result, it is given as a parenteral injection.

Competitive Landscape

Some Major Key Players In The Neostigmine Methylsulfate Injection Market:

  • Pfizer Inc.
  • Fresenius Kabi AG
  • Mylan N.V.
  • Sandoz Inc.
  • Bausch Health Companies Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Hospira (now part of Pfizer)
  • Akorn Pharmaceuticals
  • Baxter International Inc.
  • Hikma Pharmaceuticals
  • Endo International

Market Segmentation:

The neostigmine methylsulfate injection market is segmented on the basis of application, distribution channel, and end user. As per application, the market is segmented as myasthenia gravis and reversal of neuromuscular blockade. Acording to distribution channel, the market is divided into hospital, retail pharmacies, and online pharmacies. On the basis of end-users, the market is divided into hospitals, speciality clinics, and ambulatory surgical centres.

Based On Application, The Myasthenia Gravis Segment Is Accounted As A Major Contributor In The Neostigmine Methylsulfate Injection Market. 

The myasthenia gravis category is expected to hold a major share of the global neostigmine methylsulfate injection market in 2022. By increasing muscle tone, the cholinesterase inhibitor neostigmine is used to treat the indications of myasthenia gravis. Physostigmine crosses the blood-brain barrier; neostigmine does not. Since there are fewer receptors present in myasthenia gravis, blocking acetylcholinesterase increases the amount of acetylcholine that is available in the synapse and improves its ability to bind to those receptors and cause muscle contraction.

The Hospital Pharmacies Segment Witnessed Development At A Rapid Rate.

The hospital pharmacy is estimated to grow at a rapid rate in the global neostigmine methylsulfate injection market. Increasing hospitalization for treatment of the patients with myasthenia gravis and reversal of neuromuscular blockade. Furthermore, the elderly are more prone to neurological conditions like myasthenia gravis, which frequently need to be treated in hospitals with injections of neostigmine methylsulfate. The need for drugs that treat age-related illnesses, such as neostigmine methylsulfate injections, is rising as the world's elderly population keeps expanding.

In The Region, The North American Neostigmine Methylsulfate Injection Market Holds A Significant Revenue Share.

The North American neostigmine methylsulfate injection market is expected to record the maximum market share in terms of revenue in the near future. Increasing research and development in the region is anticipated to drive the market developments in the coming years. Moreover, rising FDA approvals for various competitors are expected to boost the market growth. A cholinesterase inhibitor called neostigmine methylsulfate injection is recommended for reversing the effects of non-depolarizing neuromuscular blocking drugs (NMBA) after surgery.

Neostigmine Methylsulfate Injection Market Report Scope

Report Attribute

Specifications

Market size value in 2022

USD 156.54 Mn

Revenue forecast in 2031

USD 228.43 Mn

Growth rate CAGR

CAGR of 4.4% from 2023 to 2031

Quantitative units

Representation of revenue in US$ Million and CAGR from 2023 to 2031

Historic Year

2019 to 2022

Forecast Year

2023-2031

Report coverage

The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends

Segments covered

By Application, Distribution Channel, End-User

Regional scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country scope

U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia

Competitive Landscape

Pfizer Inc., Fresenius Kabi AG, Mylan N.V., Sandoz Inc., Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Hospira (now part of Pfizer), Akorn Pharmaceuticals, and Baxter International Inc.

Customization scope

Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape.

Pricing and available payment methods

Explore pricing alternatives that are customized to your particular study requirements.

Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary

Chapter 3. Global Neostigmine Methylsulfate Injection Market Snapshot

Chapter 4. Global Neostigmine Methylsulfate Injection Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 1: By Distribution Channel Estimates & Trend Analysis
5.1. By Distribution Channel, & Market Share, 2020 & 2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Distribution Channel:

5.2.1. Hospital Pharmacies
5.2.2. Retail Pharmacies
5.2.3. Online Pharmacies

Chapter 6. Market Segmentation 2: By Application Estimates & Trend Analysis
6.1. By Application & Market Share, 2020 & 2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Application:

6.2.1. Myasthenia Gravis
6.2.2. Reversal of Neuromuscular Blockade

Chapter 7. Market Segmentation 3: By End-use Estimates & Trend Analysis
7.1. By End-use & Market Share, 2020 & 2031
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By End-use:

7.2.1. Hospitals
7.2.2. Specialty Clinics
7.2.3. Ambulatory Surgical Centers

Chapter 8. Neostigmine Methylsulfate Injection Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. North America

8.1.1. North America Neostigmine Methylsulfate Injection Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2019-2031
8.1.2. North America Neostigmine Methylsulfate Injection Market revenue (US$ Million) estimates and forecasts By Application, 2019-2031
8.1.3. North America Neostigmine Methylsulfate Injection Market revenue (US$ Million) estimates and forecasts By End-use, 2019-2031
8.1.4. North America Neostigmine Methylsulfate Injection Market revenue (US$ Million) estimates and forecasts by country, 2019-2031

8.2. Europe

8.2.1. Europe Neostigmine Methylsulfate Injection Market revenue (US$ Million) By Distribution Channel, 2019-2031
8.2.2. Europe Neostigmine Methylsulfate Injection Market revenue (US$ Million) By Application, 2019-2031
8.2.3. Europe Neostigmine Methylsulfate Injection Market revenue (US$ Million) By End-use, 2019-2031
8.2.4. Europe Neostigmine Methylsulfate Injection Market revenue (US$ Million) by country, 2019-2031

8.3. Asia Pacific

8.3.1. Asia Pacific Neostigmine Methylsulfate Injection Market revenue (US$ Million) By Distribution Channel, 2019-2031
8.3.2. Asia Pacific Neostigmine Methylsulfate Injection Market revenue (US$ Million) By Application, 2019-2031
8.3.3. Asia Pacific Neostigmine Methylsulfate Injection Market revenue (US$ Million) By End-use, 2019-2031
8.3.4. Asia Pacific Neostigmine Methylsulfate Injection Market revenue (US$ Million) by country, 2019-2031

8.4. Latin America

8.4.1. Latin America Neostigmine Methylsulfate Injection Market revenue (US$ Million) By Distribution Channel, (US$ Million) 2019-2031
8.4.2. Latin America Neostigmine Methylsulfate Injection Market revenue (US$ Million) By Application, (US$ Million) 2019-2031
8.4.3. Latin America Neostigmine Methylsulfate Injection Market revenue (US$ Million) By End-use, (US$ Million) 2019-2031
8.4.4. Latin America Neostigmine Methylsulfate Injection Market revenue (US$ Million) by country, 2019-2031

8.5. Middle East & Africa

8.5.1. Middle East & Africa Neostigmine Methylsulfate Injection Market revenue (US$ Million) By Distribution Channel, (US$ Million) 2019-2031
8.5.2. Middle East & Africa Neostigmine Methylsulfate Injection Market revenue (US$ Million) By Application, (US$ Million) 2019-2031
8.5.3. Middle East & Africa Neostigmine Methylsulfate Injection Market revenue (US$ Million) By End-use, (US$ Million) 2019-2031
8.5.4. Middle East & Africa Neostigmine Methylsulfate Injection Market revenue (US$ Million) by country, 2019-2031

Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles

9.2.1. Pfizer Inc.
9.2.2. Fresenius Kabi AG
9.2.3. Mylan N.V.
9.2.4. Sandoz Inc
9.2.5. Bausch Health Companies Inc
9.2.6. Sun Pharmaceutical Industries Ltd
9.2.7. Hospira (now part of Pfizer)
9.2.8. Akorn Pharmaceuticals
9.2.9. Baxter International Inc.
9.2.10. Hikma Pharmaceuticals
9.2.11. Endo International

Segmentation of Neostigmine Methylsulfate Injection Market-

Neostigmine Methylsulfate Injection Market By Application

  • Myasthenia Gravis
  • Reversal Of Neuromuscular Blockade

Neostigmine Methylsulfate Injection Market

Neostigmine Methylsulfate Injection Market By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Neostigmine Methylsulfate Injection Market By End User

  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers

Neostigmine Methylsulfate Injection Market By Region-

North America-

  • The US
  • Canada
  • Mexico

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • South East Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.4456

user icon
office icon
mail icon
call icon

This website is secure, and we do not share your personal information with any third party. Privacy Policy

Need Customization
Need specific information/chapter from the report of the custom data table, graph or complete report? Tell us more.

Frequently Asked Questions

How big is the Neostigmine Methylsulfate Injection Market Size?

The Neostigmine Methylsulfate Injection Market is expected to grow at a 4.4% CAGR during the forecast period for 2023-2031.

Pfizer Inc., Fresenius Kabi AG, Mylan N.V., Sandoz Inc., Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Hospira (now part of Pfizer

Our Clients

  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo

Media Citations

  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo

Growth opportunities and latent adjacency in Pharmaceuticals

Select Licence Type
$4456
$7786
$10000
$1200
Get Your GTM Strategy

Navigate market entry with channel selection, launch strategy & timeline, and pricing model support.

Equip yourself with the insights needed to develop a winning go-to-market strategy

Get real-time updates and joint control over project direction with our collaborative approach